Cover Image
市場調查報告書

第一型糖尿病 (幼年型糖尿病) :開發中產品分析

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 232787
出版日期 內容資訊 英文 576 Pages
訂單完成後即時交付
價格
Back to Top
第一型糖尿病 (幼年型糖尿病) :開發中產品分析 Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018
出版日期: 2018年05月31日 內容資訊: 英文 576 Pages
簡介

所謂第一型糖尿病 (幼年型糖尿病) ,是胰臟中斷生產胰島素的自體免疫疾病。由於人體的免疫系統攻擊、破壞胰臟內部的胰島素生產細胞 (β細胞)而發病。主要的易罹病素質有先天性疾病和家族病史、胰臟疾病、感染疾病等。主要的前兆、症狀有嚴重的乾渴和頻繁的尿意、極度的空腹感、體重減少、倦怠感、易怒,非日常性行動等。在治療時,必須改善生活習慣和定時藥物治療。

本報告提供全球第一型糖尿病 (幼年型糖尿病) 治療藥的開發中產品之開發情形相關分析,提供產品開發·上市的最新趨勢和臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

型糖尿病 (幼年型糖尿病)的概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10466IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of Type1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of Type1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type1 diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 11, 33, 29, 2, 102, 32 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 30 and 4 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Type1 diabetes (Juvenile Diabetes) - Overview
  • Type1 diabetes (Juvenile Diabetes) - Therapeutics Development
  • Type1 diabetes (Juvenile Diabetes) - Therapeutics Assessment
  • Type1 diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
  • Type1 diabetes (Juvenile Diabetes) - Drug Profiles
  • Type1 diabetes (Juvenile Diabetes) - Dormant Projects
  • Type1 diabetes (Juvenile Diabetes) - Discontinued Products
  • Type1 diabetes (Juvenile Diabetes) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Type1 diabetes (Juvenile Diabetes), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co KG, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by apceth Biopharma GmbH, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Aphios Corp, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Apodemus AB, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Arecor Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Biocon Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by BioLineRx Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Biozeus, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Boston Therapeutics Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by BTB Pharma AB, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Cellix Bio Pvt Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by DanDrit Biotech A/S, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Denceptor Therapeutics Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by DiaVacs Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici SpA, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Co, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Eloxx Pharmaceuticals Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by EpiVax Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corp, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Geropharm LLC, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by ImCyse SA, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corp, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Just Biotherapeutics Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Pvt Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by MannKind Corp, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Maruho Co Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by MedImmune LLC, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Medtronic Plc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Medy-Tox Inc, H1 2018

List of Figures

  • Number of Products under Development for Type1 diabetes (Juvenile Diabetes), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top